2796.T
Pharmarise Holdings Corporation
スタンダード · 小売業 · 小売 · JP
JPY 506.00
+0.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 66.6B | 63.5B | 54.5B | 52.0B | 51.6B |
| Cost of Revenue | 14.5B | 54.5B | 46.0B | 43.9B | 43.5B |
| Gross Profit | 2.2B | 9.0B | 8.4B | 8.1B | 8.1B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 2.1B | 8.7B | 7.5B | 6.7B | 6.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.1B | 8.7B | 7.5B | 6.7B | 6.6B |
| Cost and Expenses | 66.0B | 63.2B | 53.5B | 50.6B | 50.1B |
| Operating Income (EBIT) | 592.0M | 293.0M | 916.0M | 1.4B | 1.5B |
| Non-Operating | |||||
| Interest Income | 3.0M | 10.0M | 1.0M | 1.0M | 1.0M |
| Interest Expense | 61.0M | 178.0M | 66.0M | 55.0M | 65.0M |
| Net Interest Income | (58.0M) | (168.0M) | (65.0M) | (54.0M) | (64.0M) |
| Other Non-Op Income/Expense | (36.0M) | (157.0M) | (84.0M) | (6.0M) | (3.0M) |
| Non-Operating Income (excl Interest) | 26.0M | 95.0M | 50.0M | 75.0M | 152.0M |
| EBT (Pre-Tax Income) | 131.0M | 8.0M | 143.0M | 1.0B | 1.3B |
| Income Tax Expense | 153.0M | 390.0M | 485.0M | 702.0M | 864.0M |
| Bottom Line | |||||
| Net Income | (143.0M) | (367.0M) | (351.0M) | 333.0M | 447.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (143.0M) | (367.0M) | (351.0M) | 333.0M | 447.0M |
| Per Share | |||||
| Basic EPS | (¥13) | (¥32) | (¥33) | ¥35 | ¥48 |
| Diluted EPS | (¥13) | — | — | ¥27 | ¥36 |
| Revenue Per Share | ¥5,835 | ¥5,609 | ¥5,175 | ¥5,535 | ¥5,531 |
| Shares | |||||
| Basic Shares Outstanding | 11.4M | 11.3M | 10.5M | 9.4M | 9.3M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 1.0B | 1.5B | 2.0B | 2.1B |
| D&A | — | 730.0M | 613.0M | 589.0M | 608.0M |
| EBIT | 592.0M | 293.0M | 916.0M | 1.4B | 1.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Feb 1, 2026